Drug Topics
JUNE 4, 2024
Research presented at ENDO 2024 found that glucagon-like peptide-1 receptor agonists had a lower acute pancreatitis recurrence risk than SGLT2i, DPP4i, and no medication.
Pharmacy Times
JUNE 4, 2024
The immunizing technicians stated they had greater job satisfaction and had a greater sense of being valuable pharmacy members
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
JUNE 4, 2024
In an abstract presented at the Endocrine Society’s ENDO 2024 annual meeting in Boston, Massachusetts, researchers explored access to GLP-1s for teenagers with and without type 2 diabetes.
PharmaVoice
JUNE 4, 2024
From regulatory restrictions to evocative letter strings, branded drug naming is both an art and a science. We break down the process.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
JUNE 4, 2024
While elevated BMI at baseline was not associated with increased cardiovascular risk, cumulative excess BMI was associated with an increased risk in people under 50.
STAT
JUNE 4, 2024
Carbon dioxide monitors have been around for decades. But in 2020, they became, almost overnight, a hot commodity. All of a sudden, people wanted them to help assess the safety of indoor spaces — to gauge the likelihood of breathing in coronavirus-laced particles that until very recently had been in someone else’s lungs. No sensor can monitor how many infectious aerosols are swirling around us in real time.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
JUNE 4, 2024
Michelle Bean is drowning in batteries she doesn’t need. For two years, the batteries and electrode pads arrived each month at her home in West Boylston, Mass. In theory, they’re supposed to power a basic pain management device she ordered from a company called Zynex Medical in 2020. In reality, they sit in her closet, taking up an annoying amount of space.
Pharmacy Times
JUNE 4, 2024
The panelists expressed concerns about clinical trial data and concluded that the benefits do not outweigh the risks, but the FDA does not have to follow their recommendation.
STAT
JUNE 4, 2024
Good morning, and welcome to STAT’s live blog of the Food and Drug Administration’s scientific advisory committee meeting to review safety and efficacy data for MDMA-assisted psychotherapy to treat post-traumatic stress disorder. The discussion will start at 8:30 a.m. ET and run until about 5:30 p.m. ( here’s an agenda ). We published an in-depth story on Friday about what to expect today , but here are the basics: MDMA is the first Schedule I psychedelic to be considered by
Fierce Healthcare
JUNE 4, 2024
SCAN Health Plan secured a court victory Monday when a federal judge agreed that the Centers for Medicare & Medicaid Services (CMS) inappropriately calculated its star ratings for the 2024 plan | SCAN Health Plan secured a court victory Monday when a federal judge agreed that the Centers for Medicare & Medicaid Services inappropriately calculated its star ratings for the 2024 plan year.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
JUNE 4, 2024
Memory loss is the most obvious symptom of Alzheimer’s disease. But for the more than 6.5 million Americans who suffer from Alzheimer’s disease — and the people who support them — memory lapses are often the least of their problems. Many people with Alzheimer’s or other forms of dementia also experience mood and behavior symptoms ranging from anxiety and depression to violent outbursts and psychosis.
pharmaphorum
JUNE 4, 2024
Discover the latest advancements in life sciences R&D and quality at the Veeva R&D Quality Summit at the Marriott Auditorium Hotel in Madrid. Join industry leaders as they discuss the importance of a single source of truth.
STAT
JUNE 4, 2024
Amid rising concern over prescription drug shortages, a new report finds that the number of shortages has increased over the past decade, most are lasting longer than ever before, and the problem is affecting medicines used to treat a wide range of maladies. Specifically, the average shortage lasted for more than three years in 2023 compared to about two years in 2020, and 27 of the 125 drugs in short supply were not available for more than five years.
pharmaphorum
JUNE 4, 2024
Get insights into the exclusive interview with Mohit Manrao, AstraZeneca SVP and Head of Oncology. Explore the highlights of the conversation and ASCO 2024 here.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
JUNE 4, 2024
The federal government inappropriately lowered the 2024 Medicare Advantage star ratings of SCAN Health Plan, which led to the health insurance company in California losing hundreds of millions of dollars in bonuses from the government, a judge ruled Monday. The decision will lead to more than $250 million funneling back into SCAN, which covers 270,000 Medicare Advantage enrollees.
pharmaphorum
JUNE 4, 2024
Just a few weeks after Dexcom’s Stelo became the first over-the-counter continuous glucose monitor (CGM) to be approved by the FDA, Abbott has got the green light for its Lingo device - and analysts think uptake by patients is now poised to take off.
STAT
JUNE 4, 2024
CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for myelofibrosis. I suspect the Swiss pharma giant’s previously stated plan to submit a marketing application to the Food and Drug Administration this year has been blocked. I’m not just speculating wildly. It’s looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib — a deal pushed hard by top Novartis exec
pharmaphorum
JUNE 4, 2024
New data from a phase 2b trial of Moderna and MSD’s neoantigen melanoma vaccine may be strong enough to consider filing for accelerated approval before a phase 3 programme.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
STAT
JUNE 4, 2024
Sending patients heaps of medical supplies to score more money from insurers is common in the device industry. If insurers decline to cover the supplies, patients are stuck paying for materials they didn’t need. STAT examined one of the companies perpetuating this practice, a pain management device company called Zynex Medical, and the frustration among both its patients and former employees.
Fierce Pharma
JUNE 4, 2024
A little less than a year after Eli Lilly won the blessing of England's drug value watchdog for tirzepatide in Type 2 diabetes, the National Institute for Health and Care Excellence (NICE) has retu | A little less than a year after Eli Lilly won the blessing of England's drug value watchdog for tirzepatide in Type 2 diabetes, the National Institute for Health and Care Excellence (NICE) has returned with an endorsement in obesity.
STAT
JUNE 4, 2024
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. We’ll resume for ASCO 2025. Well, dear readers. Our ASCO reporting, including this newsletter, has come to the end. Read below for takeaway thoughts from Matt, Adam, and Angus.
Pharmaceutical Technology
JUNE 4, 2024
Scientists at the NIH have introduced an AI tool to predict the response to immune checkpoint inhibitors for cancer patients.
pharmaphorum
JUNE 4, 2024
Sleep disturbances are one of the most common and disruptive symptoms in menopausal women, but not enough is known about the causes, and current sleep aids are often ineffective. To plug that gap, Germany’s Bayer has joined forces with electronics group Samsung to carry out an observational study on sleep disturbances during menopause (SDM), tapping into the South Korean company’s position as one of the world's largest producers of consumer electronics.
Pharmaceutical Technology
JUNE 4, 2024
Alligator Bioscience’s CEO says that its pancreatic cancer drug may mark a meaningful improvement on current treatment standards.
pharmaphorum
JUNE 4, 2024
FDA advisors voted against the use of Lykos Therapeutics’ MDMA-based therapy for PTSD, in a first regulatory test for the emerging psychedelics sector
STAT
JUNE 4, 2024
Top of the morning to you, and a fine one it is. There is nothing like being greeted with clear blue skies and cool breezes upon waking up today on the Pharmalot campus. Birds are chirping, squirrels are scavenging, official mascots are barking. And we are similarly engaged in early-in-the-day rituals of our own — firing up the trusty coffee kettle for another cup of stimulation.
The Checkup by Singlecare
JUNE 4, 2024
Adderall ( dextroamphetamine-amphetamine ) is a central nervous system stimulant that’s primarily used to treat attention deficit hyperactivity disorder (ADHD) in children and adults. It’s also sometimes used to treat narcolepsy in adults and children ages 12 and older. Many expectant moms take medications for their mental health and physical well-being during pregnancy.
Fierce Pharma
JUNE 4, 2024
For several months, a U.S. security crackdown on biopharma firms suspected to be linked to the Chinese Communist Party (CCP) has continued to gain steam. | For several months, a U.S. security crackdown on biopharma firms suspected to be linked to the Chinese Communist Party has continued to gain steam. Now, several new names could be feeling the heat.
Pharmacy Times
JUNE 4, 2024
In prior studies, higher levels of physical activity were associated with higher prevalence of coronary artery calcium.
Pharmaceutical Technology
JUNE 4, 2024
A June 2024 literature review has revealed that climate change has the potential to intensify MS symptoms, as well as the incidence, prevalence, and severity of other major neurological disorders.
Pharmacy Times
JUNE 4, 2024
Compared with pembrolizumab alone, the combination treatment showed stronger recurrence-free survival and distant metastasis-free survival in patients with resected high-risk stage III or IV melanoma.
European Pharmaceutical Review
JUNE 4, 2024
Eli Lilly and Company has announced its new Executive Vice President of Global Quality. This news follows a statement by the firm at the start of this year declaring the retirement of its long-serving current EVP. A new start at Eli Lilly Melissa Seymour will begin her new role as EVP at Eli Lilly on 22 July 2024. As part of this position, she will also serve as a member of the company’s Executive Committee.
Pharmaceutical Technology
JUNE 4, 2024
Sarclisa is looking to make a dent in the anti-CD38 multiple myeloma treatment market dominated by J&J’s Darzalex.
Expert insights. Personalized for you.
357 
Let's personalize your content